GutHeart: Targeting Gut Microbiota to Treat Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.
Also called NCT02637167
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT02637167
-
- Other papers using this trial's data
- Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Norway
- Registry status
- Unknown status
Technical summary
Registry record NCT02637167. Randomized; no masking; primary purpose treatment. Start 2016-03-11 (registry gives no type); primary completion 2019-06-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GutHeart: Targeting Gut Microbiota to Treat Heart Failure
- Condition
- Systolic Heart Failure
- Intervention (Drug)
- Rifaximin
- Intervention (Drug)
- Saccharomyces boulardii
- Lead sponsor
- Oslo University Hospital
Record details
- Record id
cardio:ct-nct02637167- Content hash
9b9f0382a4197cd6c7f8ef5e6679df8c6cc16de6a79bad81db89c0df3a9574a6